| Assay ID | Title | Year | Journal | Article |
|---|
| AID649671 | Antiviral activity against HCV genotype 1 infected in human at 450 mg, po | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649649 | Antiviral activity against HCV genotype 1b infected in human Huh cells expressing luc gene by replicon assay | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649652 | Drug excretion in iv dosed bile-cannulated rat bile assessed as parent compound level after 4 hrs | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649662 | Inhibition of CYP450 | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649658 | Selectivity ratio of IC50 for cathepsin D to IC50 for HCV1b NS3/4A protease | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649648 | Selectivity ratio of IC50 human protease 3 to IC50 for HCV 1b NS3/4A protease | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649660 | Selectivity ratio of IC50 for human leukocyte protease to IC50 for HCV1b NS3/4A protease | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649664 | Inhibition of P-glycoprotein | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649670 | Antiviral activity against HCV genotype 1 infected in human at 300 mg, po | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649668 | Half life in human | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649647 | Inhibition of HCV1b NS3/4A protease | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649666 | Activity at OAT1 | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649657 | Oral bioavailability in dog at 4 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649665 | Inhibition of BSEP | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649659 | Selectivity ratio of IC50 for cathepsin L to IC50 for HCV1b NS3/4A protease | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649663 | Inhibition of human ERG up to 25 uM | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649667 | Activity at OAT2 | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649669 | Antiviral activity against HCV genotype 1 infected in human at 150 mg, po | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| AID649661 | Selectivity ratio of IC50 for porcine pancreatic elastase to IC50 for HCV1b NS3/4A protease | 2012 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
| Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |